Wegovy STEP Young Trial in Children 6 to 11 (2026): What the Data Shows
[News · Trials]

Wegovy STEP Young Trial in Children 6 to 11 (2026): What the Data Shows

NEJM, November 16, 2026 · NCT05726227 · Wegovy label · Checked November 18, 2026

Published · By Ethen Amezquita

Short answer: In the STEP Young trial, published in the New England Journal of Medicine on November 16, 2026, children aged 6 to 11 with obesity who got weekly semaglutide injections (the drug in Wegovy) had a 13.5% drop in BMI at week 68, vs a 2.7% rise on placebo, in 167 children. At week 104 the BMI change was -9.4% vs +8.4%. Wegovy is not approved for children under 12; its label says safety and effectiveness in that age group have not been established.

STEP Young tests semaglutide for obesity in children aged 6 to 11, an age group where, its authors note, data were lacking.Below is how it was run, what it found, the side effects reported, and where approval stands. We used the published abstract, the ClinicalTrials.gov record and the Wegovy label, checked November 18, 2026. The full paper may hold details the abstract does not.

How the trial worked

  • Design: phase 3, double-blind, randomized, placebo-controlled. Children were assigned 2:1 to semaglutide or placebo (abstract).
  • Who: children aged 6 to under 12 with obesity. 112 got semaglutide and 55 got placebo.
  • Dose: a weekly injection under the skin. The ClinicalTrials.gov record lists the step-up for this age group as 0.25 mg, 0.5 mg, 1 mg and 1.7 mg for four weeks each, then 2.4 mg as the maintenance dose. That is the same schedule as adult Wegovy.
  • How long: 104 weeks on treatment, then a 7-week break off the drug. Both groups got lifestyle counseling.
  • Main result: percent change in BMI (weight divided by height squared) from the start to week 68.
  • Who paid: Novo Nordisk, which makes Wegovy. Several authors work for Novo Nordisk.

The registry entry covers a larger study, NCT05726227, with 212 participants in two age groups (6 to under 12, and 12 to under 18). The paper reports the younger group. The study's overall estimated completion date is December 7, 2026.

Main results

MeasureSemaglutidePlaceboDifference
BMI change at week 68-13.5%+2.7%-16.2 points (95% CI -19.4 to -12.9)
BMI change at week 104-9.4%+8.4%-17.8 points (95% CI -22.2 to -13.3)
Moved down a BMI category by week 6879%23%Odds ratio 7.8
BMI below the obesity line (95th percentile) at week 6838%2%

All figures are from the published abstract. Two things stand out. The placebo group's BMI kept rising, so most of the gap comes from what the drug prevented as well as what it took off. And the semaglutide group's BMI change was smaller at week 104 than at week 68 (-9.4% vs -13.5%), though the gap with placebo stayed about the same. The abstract does not explain why; children are still growing, and BMI in children shifts with age.

Side effects

Adverse events were reported in 96% of children on semaglutide and 93% on placebo. Stomach and gut problems were the most common and happened more often with semaglutide. One child on semaglutide stopped because of them (abstract).

The abstract does not give rates for nausea, vomiting, gallbladder problems or other specific events. For comparison, the Wegovy label says teens 12 and older in its trial had more gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults did. Our page on side effects week by week covers the adult label data.

How it compares with the teen trial

Wegovy is approved for weight in teens 12 and older based on a 68-week trial of 201 teens. In that trial, BMI fell 16.1% on Wegovy 2.4 mg vs a 0.6% rise on placebo, according to the Wegovy label (section 14.3, Table 18). The STEP Young result at the same time point (-13.5% vs +2.7%) is in a similar range, but these are different trials in different children, not a head-to-head test.

A separate trial of tirzepatide in teens was published a day earlier. See our breakdown of the Zepbound SURMOUNT-ADOLESCENTS trial.

Where approval stands

  • The current Wegovy label (DailyMed version of June 30, 2026) covers weight reduction in adults and in children 12 and older with obesity. It says safety and effectiveness have not been established in children under 12.
  • No other drug in this class is approved for weight loss in children under 12. Mounjaro is approved for type 2 diabetes from age 10, which is a different use.
  • A published trial does not mean approval. Any change would come through an FDA review of the full data.

What this means for you

If you are a parent, this trial is a reason to ask your child's doctor about it, not a treatment plan. Semaglutide is not approved for this age group, and the trial ran with close medical follow-up and lifestyle counseling. What happens after stopping matters too: in adults, weight tends to come back, as our page on stopping and weight regain shows. Watch for the full 104-week and washout data, and for any FDA filing. Our Wegovy label summary has the approved doses.


Frequently asked questions

What is the STEP Young trial?+
A phase 3, double-blind trial of weekly semaglutide (the drug in Wegovy) vs placebo in children aged 6 to under 12 with obesity, funded by Novo Nordisk and published in the New England Journal of Medicine on November 16, 2026.
How much did BMI drop in STEP Young?+
At week 68, BMI fell 13.5% on semaglutide and rose 2.7% on placebo, a difference of 16.2 percentage points. At week 104 it was -9.4% vs +8.4%.
Is Wegovy approved for children under 12?+
No. The Wegovy label covers adults and children 12 and older with obesity and says safety and effectiveness have not been established under 12.
What side effects did children have in STEP Young?+
Adverse events occurred in 96% on semaglutide and 93% on placebo. Gut side effects were the most common and more frequent on semaglutide; one child stopped because of them.
What dose was used in STEP Young?+
The trial registry lists a weekly injection stepped up every four weeks from 0.25 mg to 1.7 mg, then 2.4 mg as the maintenance dose, the same schedule as adult Wegovy.

Sources

Every fact in this article comes from one of these sources, checked on November 18, 2026. This article is for education. It is not medical advice, and nothing here is a dose recommendation.

  1. Jastreboff AM, et al. Semaglutide for the treatment of obesity in children 6 to <12 years of age. N Engl J Med. Published online November 16, 2026. PMID 43037562. PubMed · NEJM
  2. ClinicalTrials.gov. NCT05726227: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight (STEP Young). clinicaltrials.gov
  3. Wegovy (semaglutide) label, Novo Nordisk, DailyMed version of June 30, 2026: sections 1, 8.4 and 14.3. DailyMed
  4. Mounjaro (tirzepatide) label, Eli Lilly, DailyMed version of September 2, 2026: section 1. DailyMed
  5. Kelly AS, et al. Tirzepatide in adolescents with obesity: the SURMOUNT-ADOLESCENTS randomized clinical trial. JAMA. Published online November 15, 2026. PMID 43035096. PubMed